|
eGFR (MDRD)
|
TUG
|
Subjects
|
ESRD incidence
|
Incidence ratioa
|
Model 1
|
Model 2
|
Model 3
|
Model 4
|
Competing risk model
|
|---|
|
15–29
|
−10
|
1713
|
659
|
104.26
|
1 (ref.)
|
1 (ref.)
|
1 (ref.)
|
1 (ref.)
|
1 (ref.)
|
|
10–14.9
|
627
|
223
|
97.53
|
0.94 (0.81–1.09)
|
0.98 (0.84–1.14)
|
0.96 (0.82–1.11)
|
0.99 (0.85–1.15)
|
0.96 (0.82–1.12)
|
|
151–9.9
|
112
|
52
|
124.65
|
1.20 (0.90–1.59)
|
1.32 (0.99–1.75)
|
1.26 (0.95–1.68)
|
1.19 (0.89–1.58)
|
1.12 (0.86–1.47)
|
|
20–
|
33
|
11
|
105.54
|
1.02 (0.56–1.86)
|
1.32 (0.73–2.40)
|
1.12 (0.62–2.05)
|
1.41 (0.78–2.58)
|
0.76 (0.37–1.58)
|
|
30–59
|
−10
|
114,180
|
1120
|
1.89
|
1 (ref.)
|
1 (ref.)
|
1 (ref.)
|
1 (ref.)
|
1 (ref.)
|
|
10–14.9
|
37,043
|
413
|
2.04
|
1.05 (0.93–1.17)
|
1.12 (1.00–1.25)
|
1.02 (0.91–1.14)
|
1.04 (0.93–1.16)
|
1.03 (0.92–1.16)
|
|
15–19.9
|
5510
|
71
|
2.25
|
1.13 (0.89–1.44)
|
1.22 (0.96–1.56)
|
1.03 (0.81–1.32)
|
0.97 (0.76–1.23)
|
0.93 (0.72–1.21)
|
|
20–
|
1053
|
16
|
2.72
|
1.37 (0.84–2.25)
|
1.55 (0.95–2.55)
|
1.08 (0.66–1.77)
|
1.00 (0.61–1.64)
|
0.94 (0.56–1.58)
|
|
60–89
|
−10
|
798,406
|
802
|
0.20
|
1 (ref.)
|
1 (ref.)
|
1 (ref.)
|
1 (ref.)
|
1 (ref.)
|
|
10–14.9
|
219,894
|
284
|
0.25
|
1.19 (1.04–1.36)
|
1.21 (1.05–1.38)
|
1.16 (1.01–1.33)
|
1.13 (0.99–1.30)
|
1.11 (0.97–1.28)
|
|
15–9.9
|
29,361
|
48
|
0.30
|
1.38 (1.03–1.85)
|
1.40 (1.04–1.87)
|
1.31 (0.97–1.75)
|
1.24 (0.93–1.66)
|
1.22 (0.90–1.64)
|
|
20–
|
4851
|
15
|
0.57
|
2.67 (1.60–4.46)
|
2.71 (1.63–4.53)
|
2.41 (1.44–4.01)
|
2.15 (1.29–3.59)
|
2.09 (1.25–3.50)
|
|
≥90
|
−10
|
244,827
|
151
|
0.13
|
1 (ref.)
|
1 (ref.)
|
1 (ref.)
|
1 (ref.)
|
1 (ref.)
|
|
10–14.9
|
82,712
|
64
|
0.15
|
1.18 (0.88–1.57)
|
1.20 (0.89–1.60)
|
1.17 (0.87–1.57)
|
1.16 (0.87–1.55)
|
1.15 (0.86–1.56)
|
|
15–19.9
|
10,701
|
6
|
0.11
|
0.83 (0.37–1.88)
|
0.86 (0.38–1.94)
|
0.81 (0.36–1.82)
|
0.81 (0.36–1.83)
|
0.83 (0.37–1.87)
|
|
20–
|
1758
|
3
|
0.34
|
2.59 (0.82–8.11)
|
2.66 (0.85–8.36)
|
2.53 (0.81–7.93)
|
2.52 (0.80–7.90)
|
2.48 (0.79–7.79)
|
- Model 1: crude model; Model 2: Adjusting for sex, smoking status, alcohol history, exercise level, and income; Model 3: adjusting for variables of Model 2 with BMI, DM, HT, dyslipidemia, and eGFR; Model 4: adjusting for variables of Model 3 and state of dipstick proteinuria (4 categories); Competing risk model: adjusting for variables in Model 4 and considering competing risk
- BMI body mass index, DM diabetes mellitus, eGFR estimated glomerular filtration rate using the abbreviated Modification of Diet in Renal Disease formula, ESRD end-stage renal disease, HT hypertension, TUG timed up-and-go test
- aPer 1000 person-years
